Wednesday, September 17, 2014

Tuesday Features

Cipher Pharma adopts 5-by-5 mantra for future growth

Cipher Pharma adopts 5-by-5 mantra for future growth

Cipher Pharmaceuticals (OTCBB:CPHMF; TSX:DND), with newly installed CEO, Shawn O’Brien, has adopted a five-by-five strategy that sets objectives for its future growth. Shawn O’Brien “I want to emphasize that this is not guidance, but within five years, we want our dermatology business in Canada to grow from $2-million this year to $50-million,... [Read more of this feature]


Continuum of care to drive future NOVADAQ imaging growth

Continuum of care to drive future NOVADAQ imaging growth

NOVADAQ Technologies (NASDAQ:NVDQ; TSX:NDQ), pioneers in fluorescence imaging solutions for the operating room, is now focused on manufacturing and directly marketing and selling imaging solutions for use at multiple points throughout the patient care continuum. Dr. Arun Menawat “Our continuum of care includes diagnostics that can be performed at... [Read more of this feature]


Dipexium aims to have first topical antibiotic approved for DFI

Dipexium aims to have first topical antibiotic approved for DFI

Dipexium (NASDAQ:DPRX) is enrolling patients in two pivotal Phase 3 trials of its Locilex topical antibiotic in what it hopes will be the first FDA-approved antibiotic topical cream for the treatment of mild infections of diabetic foot ulcers. From left to right, Robert DeLuccia, David Luci, David Garrett “Current treatments used off-label to treat... [Read more of this feature]


More Posts From Tuesday Features

Briefs

Avita gets FDA approval to modify ReCell trial

Avita gets FDA approval to modify ReCell trial

Avita Medical(ASX:AVH; OTCQX:AVMXY) has secured FDA approval for extensive changes to a U.S. clinical trial of ReCell, making the trial more accessible to study participants and broadening the scope of use of ReCell to improve market penetration after regulatory approval. The revised clinical program takes advantage of U.S. clinical experience within... [Read more of this brief]


Highline Research starts Evotec at buy

Highline Research starts Evotec at buy

Highline Research Advisors has initiated coverage of Evotec AG (Frankfurt Stock Exchange:EVT, TecDAX, ISIN: DE0005664809) with a “buy” rating and price target of €4. The stock closed at €3.07 on Monday. Evotec is a German-based drug discovery company operating two segments: a profitable drug discovery services business called EVT Execute that... [Read more of this brief]


Agile Therapeutics starts Phase 3 Twirla trial

Agile Therapeutics starts Phase 3 Twirla trial

Agile Therapeutics (NASDAQ:AGRX) has initiated a Phase 3 study called SECURE (Study to Evaluate Contraceptive Use, Reliability and Effectiveness) to assess the efficacy, safety and tolerability of its investigational once-weekly transdermal contraceptive patch, Twirla. Twirla is a low-dose combined hormonal contraceptive patch, which delivers the active... [Read more of this brief]


Study shows hyperosmolarity may impact cataract surgery planning

Study shows hyperosmolarity may impact cataract surgery planning

Preliminary results of the TearLab (NASDAQ:TEAR; TSX:TLB) Cataract Study were presented today at the XXXIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS). Doyle Stulting, MD, PhD The groundbreaking study evaluated the relationship of a hyperosmolar tear film on keratometry readings.  The study demonstrated that hyperosmolar... [Read more of this brief]


HCW ups Catalyst Pharma price target to $13

HCW ups Catalyst Pharma price target to $13

H.C. Wainwright has raised its price target for “buy-rated” Catalyst Pharmaceutical Partners (NASDAQ:CPRX) to $13 from $5. The stock closed at $3.09 on Friday. Catalyst’s lead program, Firdapse, is currently in the late stages of a pivotal Phase 3 program for the treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). LEMS is... [Read more of this brief]


More Posts From Briefs
Email Newsletters with Constant Contact
Google+